Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations

Abstract: There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higherthan- expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.

Saved in:
Bibliographic Details
Main Authors: Alami, Abdallah, Krewski, Daniel, Mattison, Donald, Wilson, Kumanan, Gravel, Christopher A., Villeneuve, Paul J., Farrell, Patrick J., Pérez Lloret, Santiago
Other Authors: 0000-0001-7500-0644
Format: Artículo biblioteca
Language:eng
Published: MDPI 2022
Subjects:EFECTOS ADVERSOS, VACUNAS, COVID-19, SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS, VIGILANCIA PASIVA, PERICARDITIS, MIOCARDITIS,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/15468
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-15468
record_format koha
spelling oai:ucacris:123456789-154682023-11-23T17:41:44Z Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations Alami, Abdallah Krewski, Daniel Mattison, Donald Wilson, Kumanan Gravel, Christopher A. Villeneuve, Paul J. Farrell, Patrick J. Pérez Lloret, Santiago 0000-0001-7500-0644 0000-0001-7786-7997 0000-0001-9069-6512 EFECTOS ADVERSOS VACUNAS COVID-19 SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS VIGILANCIA PASIVA PERICARDITIS MIOCARDITIS Abstract: There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higherthan- expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken. 2022-11-14T13:19:01Z 2022-11-14T13:19:01Z 2022 Artículo Alami, A. et al. Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations [en línea]. Vaccines. 2022, 10 (5). doi: 10.3390/vaccines10050722. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/15468 2076-393X (online) https://repositorio.uca.edu.ar/handle/123456789/15468 10.3390/vaccines10050722 35632478 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf MDPI Vaccines. 2022, 10 (5)
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
topic EFECTOS ADVERSOS
VACUNAS
COVID-19
SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS
VIGILANCIA PASIVA
PERICARDITIS
MIOCARDITIS
EFECTOS ADVERSOS
VACUNAS
COVID-19
SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS
VIGILANCIA PASIVA
PERICARDITIS
MIOCARDITIS
spellingShingle EFECTOS ADVERSOS
VACUNAS
COVID-19
SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS
VIGILANCIA PASIVA
PERICARDITIS
MIOCARDITIS
EFECTOS ADVERSOS
VACUNAS
COVID-19
SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS
VIGILANCIA PASIVA
PERICARDITIS
MIOCARDITIS
Alami, Abdallah
Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Pérez Lloret, Santiago
Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
description Abstract: There have been reports of cases of myocarditis and pericarditis as rare complications following mRNA COVID-19 vaccinations among young adults. While most reported cases are mild, this potential vaccine safety signal should be closely monitored. Using data from the CDC and the Vaccine Adverse Event Reporting System (VAERS), we calculated the combined reporting rate of myocarditis and pericarditis stratified by age group, sex, vaccine dose, and manufacturer, and compared these rates to the crude background incidence rates. Compared to the general population prior to the administration of the first COVID-19 vaccines in December 2020, we identified a higherthan- expected reporting rate of myocarditis and pericarditis following mRNA vaccination; the risk was higher after a second vaccine dose, higher in males than in females, and decreased with age. The highest risk was seen in males 12–17 years of age with approximately 6 cases per 100,000 second doses. Our findings suggest an increased risk of myocarditis and pericarditis in young males following a second dose of an mRNA COVID-19 vaccine. Since these findings are based on safety signals derived from passive surveillance data, confirmatory epidemiological studies should be undertaken.
author2 0000-0001-7500-0644
author_facet 0000-0001-7500-0644
Alami, Abdallah
Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Pérez Lloret, Santiago
format Artículo
topic_facet EFECTOS ADVERSOS
VACUNAS
COVID-19
SISTEMA DE NOTIFICACIÓN DE EVENTOS ADVERSOS DE VACUNAS
VIGILANCIA PASIVA
PERICARDITIS
MIOCARDITIS
author Alami, Abdallah
Krewski, Daniel
Mattison, Donald
Wilson, Kumanan
Gravel, Christopher A.
Villeneuve, Paul J.
Farrell, Patrick J.
Pérez Lloret, Santiago
author_sort Alami, Abdallah
title Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
title_short Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
title_full Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
title_fullStr Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
title_full_unstemmed Risk of myocarditis and pericarditis among young adults following mRNA COVID-19 vaccinations
title_sort risk of myocarditis and pericarditis among young adults following mrna covid-19 vaccinations
publisher MDPI
publishDate 2022
url https://repositorio.uca.edu.ar/handle/123456789/15468
work_keys_str_mv AT alamiabdallah riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT krewskidaniel riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT mattisondonald riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT wilsonkumanan riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT gravelchristophera riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT villeneuvepaulj riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT farrellpatrickj riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
AT perezlloretsantiago riskofmyocarditisandpericarditisamongyoungadultsfollowingmrnacovid19vaccinations
_version_ 1787224525160579072